amd

Ranibizumab is a humanized monoclonal antibody fragment designed to target and inhibit vascular endothelial growth factor (VEGF), including VEGF110, VEGF121, and VEGF165. Ranibizumab's ability to selectively target and neutralize VEGF-A isoforms has made it a crucial component of research and treatment strategies for wet wet age-related macular degeneration (AMD).

Amdokitug is a humanized monoclonal antibody of the IgG1κ class that targets IL17A.

Lampalizumab (RG 7417) is a humanized monoclonal antibody targeting Complement Factor D in the complement pathway, used in age-related macular degeneration (AMD) and cardiovascular disease research.

Tarcocimab (OG1953), a humanized IgG1-type anti-VEGFA monoclonal antibody, is utilized in research targeting conditions such as retinal vein occlusion (RVO) and wet age-related macular degeneration (AMD).

Galegenimab (FHTR 2163; RG 6147; RO 7171009), an antibody fragment targeting High-temperature requirement A1 (HTRA1), is utilized in research on age-related macular degeneration (AMD) [1].

Faricimab, a bispecific antibody targeting Angiopoietin-2 (Ang-2) and VEGF-A. Faricimab prevents retinal ischemia/reperfusion (I/R) injury and vascular leakage, cell death, and inflammation in sCNV mouse models, showing superior visual acuity improvement over ranibizumab for retinal diseases including w-AMD, DME, and RVO.

Brolucizumab (DLX1008) is a single-chain variable fragment (scFv) anti-VEGF-A antibody exhibiting an exceptionally low picomolar binding affinity (K D = 1.05 pM). through its potent blockade of vascular endothelial growth factor A (VEGF-A), Brolucizumab effectively reduces pathological neovascularization and vascular leakage within the macula and is under investigation for the treatment of neovascular (wet) age-related macular degeneration (AMD).